A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria (clinicaltrials.gov) - Oct 7, 2022 - P2 | N=25 | Recruiting | Sponsor: United BioPharma | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|